BlossomHill Therapeutics (BLSM) investor relations material

Executive summary

• Focused on developing small molecule medicines for cancer, with three main programs: BH-30643 (OMNI-EGFR inhibitor), BH-30236 (CLK inhibitor), and preclinical BH-501284 (pan-KRAS inhibitor).

• Completed an upsized $168.3 million IPO in August 2026, significantly strengthening the balance sheet.

• Achieved FDA Fast Track designation for BH-30643 for advanced EGFR C797S-positive NSCLC.

• Presented promising clinical and preclinical data for pipeline assets at major oncology conferences.

• Expanded Board of Directors with two new appointments.

Financial highlights

• Q2 2026 net loss: $23.8 million, up from $13.2 million in Q2 2025.

• Research and development expenses for Q2 2026: $21.4 million, up from $12.5 million year-over-year.

• G&A expenses increased to $3.3 million from $1.6 million year-over-year, mainly due to legal and personnel expenses.

• Cash and cash equivalents as of June 30, 2026: $95.4 million, prior to IPO proceeds.

• IPO gross proceeds of $168.3 million expected to fund operations into Q2 2028.

Outlook and guidance

• Existing cash and IPO proceeds expected to fund operations into Q2 2028.

• Pivotal Phase 2 trial for BH-30643 in C797S-positive NSCLC planned for Q1 2027.

• Updated clinical data for BH-30643 and BH-30236 expected throughout 2027.

• IND submission for BH-501284 planned for Q1 2027.

• End-of-Phase 1 meeting for BH-30643 scheduled for Q4 2026.